within Pharmacolibrary.Drugs.ATC.L;

model L03AX16
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.87,
    Cl             = 0.0025,
    adminDuration  = 600,
    adminMass      = 0.24,
    adminCount     = 1,
    Vd             = 0.0003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Plerixafor is a hematopoietic stem cell mobilizer that acts as a CXCR4 antagonist. It is used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. Plerixafor is currently approved by regulatory agencies such as FDA and EMA for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy volunteers and patients with multiple myeloma or non-Hodgkin’s lymphoma, adults of both sexes; after a single subcutaneous injection.</p><h4>References</h4><ol><li><p>Keating, GM (2011). Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. <i>Drugs</i> 71(12) 1623–1647. DOI:<a href=&quot;https://doi.org/10.2165/11206040-000000000-00000&quot;>10.2165/11206040-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21861545/&quot;>https://pubmed.ncbi.nlm.nih.gov/21861545</a></p></li><li><p>Wagstaff, AJ (2009). Plerixafor: in patients with non-Hodgkin&#x27;s lymphoma or multiple myeloma. <i>Drugs</i> 69(3) 319–326. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200969030-00007&quot;>10.2165/00003495-200969030-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19275275/&quot;>https://pubmed.ncbi.nlm.nih.gov/19275275</a></p></li><li><p>Choi, HY, et al., &amp; Yoo, BK (2010). Plerixafor for stem cell mobilization in patients with non-Hodgkin&#x27;s lymphoma and multiple myeloma. <i>The Annals of pharmacotherapy</i> 44(1) 117–126. DOI:<a href=&quot;https://doi.org/10.1345/aph.1M380&quot;>10.1345/aph.1M380</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20009003/&quot;>https://pubmed.ncbi.nlm.nih.gov/20009003</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L03AX16;
